Search - tctmd.com

Displaying 1 - 20 of 561

Sort: Relevancy | Date

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

December 26, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

April 24, 2025

Top Endovascular News of 2024

News Daily News

Top Endovascular News of 2024

December 28, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

DES Best for In-Stent Restenosis, but DCBs Also Viable

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

FDA Approves Bioresorbable Scaffold for BTK Lesions

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Top Endovascular News of 2023

News Daily News

Top Endovascular News of 2023

December 28, 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

October 31, 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

News Conference News ESC 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

August 26, 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

May 31, 2023

Some Rays of Hope for ‘Sorry State’ of Transplant Rejection

News Features

Some Rays of Hope for ‘Sorry State’ of Transplant Rejection

May 08, 2023

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.